Boehringer Ingelheim has been cited by Britain’s Prescription Medicines Code of Practice Authority (PMCPA) for the way the company provides information about Pradaxa on their website.
Free Pradaxa Lawsuit Evaluation: If you or a loved one has been injured by Pradaxa, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer and our lawyers can help.
What’s the problem?
March 14, 2012 – The new charges being leveled against Boehringer were brought by an as-of-yet unnamed physician who began delving into the issue after seeing a press release by the company that described Pradaxa as a ‘wonder drug’ and competitor Coumadin (generic: warfarin) as ‘rat poison.’ The press release also reportedly failed to properly warn of the potential internal bleeding side effects that have been increasingly associated with Pradaxa use.
A subsequent investigation led to the PMCPA’s ruling that the Pradaxa website was in violation of the Association of the British Pharmaceutical Industry’s (ABPI) code of practice. The site was originally intended to be for medical professionals only, but there have been numerous complaints that it targets marketing of the drug instead. To date, the violations against Boehringer have yet to be published in a report.
The violations come as Pradaxa is under fire from health regulators in the United States, Europe and Canada, which have all launched independent investigations into the potential adverse health complications linked to the new blood-thinner drug.
First approved by the U.S. Food & Drug Administration (FDA) in October 2010, Pradaxa is marketed as a superior alternative to Coumadin for the prevention of strokes among patients with atrial fibrillations. Unfortunately, since its release, there have been a shocking number of adverse event reports involving severe hemorrhages among Pradaxa users, including hundreds of deaths from the drug.
Among users of Coumadin, internal bleeding side effects can be addressed with a single dose of Vitamin K. Despite the fact that Pradaxa has been marketed as a superior alternative because it allegedly requires less intensive monitoring, internal bleeding events cannot be counteracted with Vitamin K in users of the drug.
According to a January 2012 report issued by the Institutes for Safe Medication Practices, more cases of severe hemorrhages from Pradaxa were reported to the FDA’s Adverse Event Reporting System during the first quarter of 2011 than with any other drug monitored by the group. During that short time period, at least 505 instances involving Pradaxa bleeding events were reported, compared to just 176 cases reported with Coumadin, which came in second on the list.
As the controversy surrounding Pradaxa’s internal bleeding side effects has grown in recent months, so too has the number of lawsuits filed over the drug increased dramatically. The vast majority of these complaints allege that Boehringer was negligent in failing to adequately research their drug, or warn about the risk of serious and potentially life-threatening internal bleeding events associated with Pradaxa use.
Do I Have a Pradaxa Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Pradaxa lawsuits. We are handling individual litigation nationwide and currently accepting new cases in all 50 states.
Free Confidential Case Evaluation: Again, if you or a loved one was injured by Pradaxa, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.